Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on XERS stock, giving a Buy rating on May 9.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Roanna Ruiz’s rating is based on Xeris Pharmaceuticals’ impressive financial performance and strategic growth initiatives. The company reported strong first-quarter revenues of $60.1 million, marking a significant year-over-year growth of approximately 48%. This consistent growth trend, along with management’s increased confidence reflected in their tightened full-year revenue guidance, suggests a stable and promising investment opportunity.
Moreover, the substantial growth of Recorlev, with a remarkable 141% increase in revenue driven by a 124% rise in average patients, highlights its role as a primary growth driver. The achievement of positive adjusted EBITDA for the third consecutive quarter further underscores Xeris’ operational improvements. Upcoming catalysts, such as discussions on XP-8121, and a solid cash position of $58.4 million, position the company well for continued success, supporting the Buy rating.
Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and Lantheus. According to TipRanks, Ruiz has an average return of -15.1% and a 30.63% success rate on recommended stocks.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.